Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00940017 · ClinicalTrials.gov registry record · Phase 4

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

A Phase 4 study, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
24
Enrollment target

NCT00940017: Completed Phase 4 study, sponsored by Pfizer.

NCT00940017 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00940017, a Phase 4 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

Primary Outcome

Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL). Observed directly from the data. Collected on Day 3.

Interventions

  • DRUG anidulafungin and voriconazole

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-09
Est. Completion 2008-10
Phase Phase 4
Pfizer

1,845 total trials

What the finished NCT00940017 record still lists

NCT00940017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which anidulafungin and voriconazole is the first listed.

NCT00940017 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00940017 about?

NCT00940017 is a clinical study titled "A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects". The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

What is the current status of trial NCT00940017?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2008-09. Estimated completion is 2008-10.

What interventions are being tested in trial NCT00940017?

The interventions under investigation include: anidulafungin and voriconazole (DRUG).

Who is sponsoring clinical trial NCT00940017?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00940017's enrollment target sits among peer trials

24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00940017, the US trial registry maintained by the National Library of Medicine. NCT00940017 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.